🧬 Targeting Aldosterone: A New Shot at Hypertension 🎯💥

🚨 New breakthrough in hypertension care!   💊 The Launch-HTN trial shows lorundrostat — a selective aldosterone synthase inhibitor — significantly lowers systolic BP in patients with uncontrolled or treatment-resistant hypertension.   📉 −16.9 mmHg vs −7.9 mmHg with placebo (P 🧪 Safe, well-tolerated, and effective across subgroups.   A potential game-changer in aldosterone-targeted therapy! 🔄💥 #Hypertension #Cardiology #ClinicalTrials #PrecisionMedicine